A diverse and broad development pipeline

Seagen®

Late-stage[a]



[a] The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

[b] Program being developed in collaboration with Takeda Pharmaceutical Company, Ltd.
[c] Program being co-developed with Astellas Pharma Global Development, Inc.
[d] Trial being conducted by the Alliance for Clinical Trials in Oncology.
[f] Study sponsored by Astellas Pharma Global Development, Inc., in collaboration with Seagen Inc. and Merck Sharp & Dohme LLC
[g] Study sponsored by Merck Sharp & Dohme LLC, in collaboration with Seagen Inc. and Astellas Pharma Global Development, Inc.
[h] Trial being co-developed with Merck Sharp & Dohme LLC
[j] Trial in collaboration with RemeGen Co., Ltd. and Merck Sharp & Dohme LLC
[k] Phase 1/2
[l] Phase 1b/2

A diverse and broad development pipeline

Seagen®

Late-stage (continued)[a]

PHASE 1 | PHASE 2 | PHASE 3

TISOTUMAB VEDOTIN (TV)[e]	innovaTV 301: Recurrent or metastatic cervical cancer
	innovaTV 205[l]: Recurrent or metastatic cervical cancer (monotherapy and in combination with other agents)
	innovaTV 207: Advanced solid tumors
LADIRATUZUMAB VEDOTIN (LV)[i]	SGNLVA-005: Locally advanced or metastatic solid tumors
	SGNLVA-002/KEYNOTE-721[l]: First-line locally advanced or metastatic triple-negative breast cancer (LV + pembrolizumab)
	SGNLVA-001: Locally advanced or metastatic breast cancer, including triple-negative breast cancer
DISITAMAB VEDOTIN (DV)	RC48 G001[j]: Locally advanced or metastatic urothelial carcinoma with HER2 expression (DV ± pembrolizumab)

Early-stage[a]

SEA-BCMA	SGNBCMA-001: Relapsed/refractory multiple myeloma
SEA-CD40	SGNS40-002: Melanoma and NSCLC (SEA-CD40 ± anti-PD1 ± chemotherapy)
	SGNS40-001: Advanced solid tumors and lymphomas (SEA-CD40 ± anti-PD1 ± chemotherapy)
SEA-CD70	SGNS70-101: Myelodysplastic syndrome and acute myeloid leukemia
SEA-TGT	SGNTGT-001: Advanced solid tumors and lymphomas (SEA-TGT ± sasanlimab)
SGN-ALPV	SGNALPV-001: Advanced solid tumors
SGN-BB228	SGN-BB228-001: Advanced melanoma and solid tumors
SGN-B6A	SGNB6A-001: Advanced solid tumors
SGN-B7H4V	SGNB7H4V-001: Advanced solid tumors
SGN-CD228A	SGN228A-001: Advanced solid tumors
SGN-PDL1V	SGNPDL1V-001: Advanced solid tumors
SGN-STNV	SGNSTNV-001: Advanced solid tumors

[a] The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

[e] Program being co-developed with Genmab A/S
[i] Program being co-developed with Merck Sharp & Dohme LLC
[j] Trial in collaboration with RemeGen Co., Ltd. and Merck Sharp & Dohme LLC
[l] Phase 1b/2

A + AVD: brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine; **AN + AD:** brentuximab vedotin, nivolumab, doxorubicin and dacarbazine; **AYA:** adolescents and young adults; **CD:** cluster of differentiation; **CHP:** cyclophosphamide; doxorubicin, and prednisone; **DLBCL:** diffuse large B-cell lymphoma; **G-CSF:** granulocyte colony stimulating factors; **HER2:** human epidermal growth factor receptor 2; **HIV:** human immunodefiency virus; **MIBC:** muscle invasive bladder cancer; **NSCLC:** non–small cell lung cancer; **PD-1:** programmed cell death protein 1; **PTCL:** peripheral T-cell lymphoma; **RC + PLND:** radical cystectomy plus pelvic lymph node dissection; **T-DM1:** ado-trastuzumab emtansine